NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apellis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $43.04 +2.54 (+6.27 %) (As of 01/22/2020 01:27 AM ET) Add Compare Today's Range$40.17Now: $43.04▼$43.1450-Day Range$23.99MA: $31.97▼$43.0452-Week Range$12.50Now: $43.04▼$43.14Volume1.67 million shsAverage Volume3.71 million shsMarket Capitalization$3.22 billionP/E RatioN/ADividend YieldN/ABeta0.68 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS Previous Symbol CUSIPN/A CIK1492422 Webhttp://www.apellis.com/ Phone502-241-4114Debt Debt-to-Equity Ratio1.09 Current Ratio10.12 Quick Ratio10.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.86 per share Price / Book15.05Profitability EPS (Most Recent Fiscal Year)($2.34) Net Income$-127,500,000.00 Net MarginsN/A Return on Equity-127.91% Return on Assets-67.08%Miscellaneous Employees87 Outstanding Shares74,863,000Market Cap$3.22 billion Next Earnings Date2/25/2020 (Estimated) OptionableNot Optionable Receive APLS News and Ratings via Email Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:APLS Rates by TradingView Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions What is Apellis Pharmaceuticals' stock symbol? Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS." How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals Inc (NASDAQ:APLS) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($1.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.01) by $0.09. View Apellis Pharmaceuticals' Earnings History. When is Apellis Pharmaceuticals' next earnings date? Apellis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Apellis Pharmaceuticals. What price target have analysts set for APLS? 10 Wall Street analysts have issued 12 month price objectives for Apellis Pharmaceuticals' shares. Their forecasts range from $23.00 to $80.00. On average, they expect Apellis Pharmaceuticals' stock price to reach $46.09 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals. What is the consensus analysts' recommendation for Apellis Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals. What are Wall Street analysts saying about Apellis Pharmaceuticals stock? Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock: 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (12/24/2019) 2. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating on Apellis and lowering our 12-month price target to $52 from $57. This morning, Apellis issued a press release highlighting financial and corporate updates for the period ended on 3/31. Our decrease in price target is based off an increased share count, due to the recent March 2019 financing, and an increase to R&D and SG&A projections. With Phase 3 PEGASUS (PNH) enrollment expected to complete by the end of 2Q19, we believe APLS shares represent a strong buying opportunity, ahead of a potential 4Q19 data readout. Below we revisit our thoughts on APL-2 and its potential to be a disruptive addition to the PNH market." (5/8/2019) Has Apellis Pharmaceuticals been receiving favorable news coverage? News articles about APLS stock have trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Apellis Pharmaceuticals. Who are some of Apellis Pharmaceuticals' key competitors? Some companies that are related to Apellis Pharmaceuticals include Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Horizon Therapeutics (HZNP), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and The Medicines (MDCO). What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Fate Therapeutics (FATE), KemPharm (KMPH), Anavex Life Sciences (AVXL), Genocea Biosciences (GNCA), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI) and Exelixis (EXEL). Who are Apellis Pharmaceuticals' key executives? Apellis Pharmaceuticals' management team includes the folowing people: Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)Mr. Ahmad Sadr, VP of Technical Operations When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.11%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Lukas Scheibler, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals. Which major investors are buying Apellis Pharmaceuticals stock? APLS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Apellis Pharmaceuticals' stock price today? One share of APLS stock can currently be purchased for approximately $43.04. How big of a company is Apellis Pharmaceuticals? Apellis Pharmaceuticals has a market capitalization of $3.22 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals. What is Apellis Pharmaceuticals' official website? The official website for Apellis Pharmaceuticals is http://www.apellis.com/. How can I contact Apellis Pharmaceuticals? Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected] MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 154 (Vote Underperform)Total Votes: 336MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2020 by MarketBeat.com StaffFeatured Article: Guidelines for Successful Channel Trading
